

Contacts:

Mirasol Panlilio, VP Marketing and Sales
VeraLight, Inc.
505.272.7023
Mirasol.panlilio@veralight.com

FOR IMMEDIATE RELEASE

VERALIGHT NAMES LINDA MACKOWIAK DIRECTOR OF SCIENTIFIC
AFFAIRS AND CLINICAL APPLICATIONS

ALBUQUERQUE, N.M., March 31, 2008 — VeraLight, Inc., a privately held medical company, announced the appointment of Linda Mackowiak, MS RN CDE, as the company's new Director of Scientific Affairs and Clinical Applications. Ms Mackowiak will spearhead efforts to foster clinical utilization of the company's proprietary SCOUT DS™ technology to non-invasively screen for type 2 diabetes and pre-diabetes.

Mr. David Van Avermaete, CEO of VeraLight, commented, "We are very excited and fortunate that Linda has joined the VeraLight team. With more than 26 years of experience in the diabetes clinical and research field, Linda brings a comprehensive skill set that will be instrumental in helping the clinical community apply the SCOUT DS test in practice once approved. She has an excellent track record in both the industry and clinical sectors. Her expertise will be of great value as we move from the development to commercial phase of our operation."

Prior to joining VeraLight, Ms Mackowiak most recently was with Abbott Diabetes Care as a Clinical Science Manager and Medtronic Diabetes as a Glucose Sensor Specialist and Senior Clinical Research Specialist. Before her move to industry, she was in adult and pediatric clinical nurse practice for 18 years. Ms Mackowiak holds a Master of Science degree in Nursing and is a Registered Nurse, Nurse Practitioner, and Certified Diabetes Educator.

About VeraLight

VeraLight, Inc., based in Albuquerque, New Mexico, is applying its proprietary Spectroscopic Advanced Glycation Endproduct (SAGE) detection technology to develop the SCOUT DS system — intended to be the first non-invasive diabetes screening system that provides healthcare professionals with a more accurate and convenient method for detecting type 2 diabetes and pre-diabetes based on the presence of advanced glycation endproduct biomarkers found in skin. Weighing about 10 pounds, the SCOUT DS is a designed to be simple-to-use device that does will require no blood draw, no fasting and no waiting for a lab result. For more information see <http://www.veralight.com>.

###